A detailed history of Pier 88 Investment Partners LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Pier 88 Investment Partners LLC holds 59,170 shares of DNLI stock, worth $1.43 Million. This represents 2.26% of its overall portfolio holdings.

Number of Shares
59,170
Previous 69,370 14.7%
Holding current value
$1.43 Million
Previous $1.61 Million 7.02%
% of portfolio
2.26%
Previous 1.85%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$20.96 - $31.05 $213,792 - $316,710
-10,200 Reduced 14.7%
59,170 $1.72 Million
Q2 2024

Aug 06, 2024

BUY
$14.96 - $23.22 $439,824 - $682,668
29,400 Added 73.56%
69,370 $1.61 Million
Q1 2024

May 10, 2024

SELL
$15.83 - $23.35 $83,424 - $123,054
-5,270 Reduced 11.65%
39,970 $820,000
Q4 2023

Feb 09, 2024

SELL
$16.2 - $23.18 $88,452 - $126,562
-5,460 Reduced 10.77%
45,240 $970,000
Q3 2023

Nov 09, 2023

BUY
$20.63 - $30.17 $62,302 - $91,113
3,020 Added 6.33%
50,700 $1.05 Million
Q2 2023

Aug 07, 2023

BUY
$23.37 - $32.96 $113,110 - $159,526
4,840 Added 11.3%
47,680 $1.41 Million
Q1 2023

May 09, 2023

BUY
$21.91 - $32.67 $166,516 - $248,292
7,600 Added 21.57%
42,840 $987,000
Q4 2022

Feb 08, 2023

BUY
$26.28 - $33.92 $608,382 - $785,248
23,150 Added 191.48%
35,240 $980,000
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $25,710 - $38,144
-990 Reduced 7.57%
12,090 $371,000
Q2 2022

Aug 12, 2022

BUY
$20.88 - $35.19 $272,901 - $459,933
13,070 Added 130700.0%
13,080 $385,000
Q1 2022

May 13, 2022

SELL
$29.0 - $47.27 $959,030 - $1.56 Million
-33,070 Reduced 99.97%
10 $0
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $604,778 - $781,284
14,200 Added 75.21%
33,080 $1.48 Million
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $230,764 - $372,374
4,760 Added 33.71%
18,880 $952,000
Q2 2021

Aug 13, 2021

BUY
$50.3 - $78.44 $329,968 - $514,566
6,560 Added 86.77%
14,120 $1.11 Million
Q1 2021

May 14, 2021

SELL
$53.8 - $81.53 $283,257 - $429,255
-5,265 Reduced 41.05%
7,560 $432,000
Q4 2020

Feb 12, 2021

SELL
$36.89 - $93.56 $847,363 - $2.15 Million
-22,970 Reduced 64.17%
12,825 $3.3 Million
Q3 2020

Nov 16, 2020

SELL
$23.13 - $38.84 $381,968 - $641,403
-16,514 Reduced 31.57%
35,795 $1.28 Million
Q2 2020

Aug 14, 2020

BUY
$16.01 - $28.82 $73,790 - $132,831
4,609 Added 9.66%
52,309 $1.27 Million
Q1 2020

May 15, 2020

BUY
$14.2 - $27.98 $80,940 - $159,486
5,700 Added 13.57%
47,700 $835,000
Q4 2019

Feb 14, 2020

BUY
$14.4 - $19.99 $20,016 - $27,786
1,390 Added 3.42%
42,000 $732,000
Q3 2019

Nov 14, 2019

BUY
$15.32 - $21.92 $198,547 - $284,083
12,960 Added 46.87%
40,610 $622,000
Q2 2019

Aug 08, 2019

SELL
$18.5 - $28.14 $153,180 - $232,999
-8,280 Reduced 23.04%
27,650 $574,000
Q1 2019

May 15, 2019

BUY
$17.99 - $24.65 $176,301 - $241,570
9,800 Added 37.5%
35,930 $834,000
Q4 2018

Feb 11, 2019

SELL
$13.88 - $21.75 $163,784 - $256,650
-11,800 Reduced 31.11%
26,130 $540,000
Q3 2018

Nov 14, 2018

BUY
$12.46 - $21.74 $472,607 - $824,598
37,930 New
37,930 $825,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.24B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Pier 88 Investment Partners LLC Portfolio

Follow Pier 88 Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier 88 Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier 88 Investment Partners LLC with notifications on news.